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MaBACKGROUND Transvenous implantable cardioverter-deﬁbrillators (TV-ICDs) improve survival in patients at risk for
sudden cardiac death, but complications remain an important drawback. The subcutaneous ICD (S-ICD) was developed to
overcome lead-related complications. Comparison of clinical outcomes of both device types in previous studies was
hampered by dissimilar patient characteristics.
OBJECTIVES This retrospective study compares long-term clinical outcomes of S-ICD and TV-ICD therapy in a
propensity-matched cohort.
METHODS The authors analyzed 1,160 patients who underwent S-ICD or TV-ICD implantation in 2 high-volume hos-
pitals in the Netherlands. Propensity matching for 16 baseline characteristics, including diagnosis, yielded 140 matched
pairs. Clinical outcomes were device-related complications requiring surgical intervention, appropriate and inappropriate
ICD therapy, and were reported as 5-year Kaplan-Meier rate estimates.
RESULTS All 16 baseline characteristics were balanced in the matched cohort of 140 patients with S-ICDs and 140
patients with TV-ICDs (median age 41 years [interquartile range: 30 to 52 years] and 40% women). The complication rate
was 13.7% in the S-ICD group versus 18.0% in the TV-ICD group (p ¼ 0.80). The infection rate was 4.1% versus 3.6% in
the TV-ICD groups (p ¼ 0.36). Lead complications were lower in the S-ICD arm compared with the TV-ICD arm, 0.8%
versus 11.5%, respectively (p ¼ 0.03). S-ICD patients had more nonlead-related complications than TV-ICD patients,
9.9% versus 2.2%, respectively (p ¼ 0.047). Appropriate ICD intervention (antitachycardia pacing and shocks) occurred
more often in the TV-ICD group (hazard ratio [HR]: 2.42; p ¼ 0.01). The incidence of appropriate (TV-ICD HR: 1.46;
p ¼ 0.36) and inappropriate shocks (TV-ICD HR: 0.85; p ¼ 0.64) was similar.
CONCLUSIONS The complication rate in patients implanted with an S-ICD or TV-ICD was similar, but their nature
differed. The S-ICD reduced lead-related complications signiﬁcantly, at the cost of nonlead-related complications. Rates
of appropriate and inappropriate shocks were similar between the 2 groups. (J Am Coll Cardiol 2016;68:2047–55)
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ABBR EV I A T I ON S
AND ACRONYMS
AMC = Academic Medical
Center
ATP = antitachycardia pacing
CI = conﬁdence interval
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
IQR = interquartile range
LUMC = Leiden University
Medical Center
SCD = sudden cardiac death
S-ICD = subcutaneous
implantable cardioverter-
deﬁbrillator
TV-ICD = transvenous
implantable cardioverter-
deﬁbrillator
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
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2048leads are associated with both infective and
mechanical complications, such as lead endo-
carditis, pneumothorax, venous occlusion,
and cardiac perforation (4,5). Lead failure
may cause inappropriate shocks and impede
delivery of appropriate therapy for ventricu-
lar arrhythmias (6–8).SEE PAGE 2056The subcutaneous implantable cardioverter-
deﬁbrillator (S-ICD) was designed to eliminate
complications related to transvenous leads,
but lacks pacing capabilities and can therefore
only be used in patients without a need for
pacing (9). Studies of the S-ICD have demon-
strated clinical efﬁcacy, but also reported a
13.1% inappropriate shock rate at 3 years
follow-up, which was signiﬁcantly reduced
with dual-zone programming (10–12). How-
ever, direct comparison of clinical outcomes
of the available S-ICD cohorts to TV-ICDcohorts is limited by varying patient characteristics,
follow-up durations, and deﬁnitions of complications.
The objective of the current retrospective study is
to compare long-term clinical outcomes of S-ICD and
TV-ICD therapy in a propensity score–balanced cohort.
METHODS
STUDY SETTING. Patients with ICDs implanted in 2
hospitals in the Netherlands, Academic Medical
Center (AMC) and Leiden University Medical Center
(LUMC), were included. For this analysis, patients
implanted with single- and dual-chamber TV-ICDs
between 2005 and 2014 at the LUMC, and patients
implanted with S-ICDs between 2009 and 2015 at the
AMC were selected. During this period of time, LUMC
had not adopted the S-ICD into their clinical practice,
and therefore, this variation in practice between
AMC and LUMC was used to compare the 2 types
of ICD therapy. Patients included in the ongoing
PRAETORIAN (Prospective, RAndomizEd comparison
of subcuTaneOus and tRansvenous ImplANtable
cardioverter-deﬁbrillator therapy) trial were excluded
from this analysis (13). The need for informed consent
was waived in both centers due to the observational
nature of the study.
STUDY POPULATION. At the LUMC, 1,312 patients
received a TV-ICD between 2005 and 2014. In the
AMC, 148 patients were implanted with an S-ICD
between 2009 and 2015. Because baseline character-
istics were signiﬁcantly different, we used propensity
score matching as the primary analysis. The devices
used were S-ICDs (Boston Scientiﬁc, Marlborough,Massachusetts) and TV-ICDs (Biotronik, Berlin,
Germany; Boston Scientiﬁc; Medtronic, Dublin,
Ireland; and St. Jude Medical, Saint Paul, Minnesota).
The majority of both S-ICD and TV-ICD patients were
implanted under local anesthesia, according to the
prevailing local hospital protocol (14). LUMC is an
experienced implantation center for TV-ICDs, as is
AMC for S-ICDs and TV-ICDs.
DATA COLLECTION. Data collection in both centers
was performed at regular intervals by reviewing
medical records for baseline characteristics, implan-
tation data, and follow-up data on clinical outcomes,
complications, and therapy delivery. The survival
status of patients was retrieved from municipal civil
registries.
DEFINITION OF OUTCOMES. Complications were
deﬁned as all device related complications requiring
surgical intervention. Lead complications were
deﬁned as complications requiring replacement or
repositioning of the lead, without elective pulse
generator replacement. In addition, lead survival was
deﬁned as the time between lead implantation and
lead failure, with or without elective pulse generator
replacement. Appropriate therapy consisted of anti-
tachycardia pacing (ATP) only and shocks (whether
preceded by ATP or not) for ventricular tachycardia
(VT) or ventricular ﬁbrillation (VF). Inappropriate
therapy consisted of ATP and shocks for heart
rhythms other than VT or VF. Local electrophysiolo-
gists adjudicated all arrhythmia episodes.
STATISTICAL ANALYSIS. Ent i re cohort . Categorical
variables were presented as numbers and percent-
ages, and were compared for the entire cohort using
the Fisher exact test. On the basis of their distribu-
tions, continuous variables are presented as mean 
SD or median with interquartile range (IQR) (25th to
75th) and compared using the Student t test or
Wilcoxon rank sum test.
PROPENSITY SCORE MATCHING. Propensity score
matching was performed with patients for whom
complete baseline variables were available (total
N ¼ 1,154). Analysis of excluded patients due to
missing baseline data did not suggest selection bias.
We used logistic multivariable regression with device
type (S-ICD or TV-ICD) as the dependent variable and
16 baseline variables as independent predictors to
calculate the propensity score (Table 1, Online Table
1). The Harrell’s C-statistic for the propensity score
logistic regression model was 0.89. Patients were 1-
to-1 greedy matched using the nearest-neighbor
method. There was sufﬁcient overlap in the pro-
pensity scores to individually match each S-ICD case
to a TV-ICD control (Online Figure 1).
TABLE 1 Baseline Characteristics of the Unmatched and Matched Cohorts
Entire Cohort Complete Cases Propensity Score–Matched Cohort
S-ICD Group
(n ¼ 148)
TV-ICD Group
(n ¼ 1,312)
Standardized
Mean Difference* p Value
S-ICD Group
(n ¼ 140)
TV-ICD Group
(n ¼ 140)
Standardized
Mean Difference* p Value
Age, yrs 41 (26-52) 62 (52-70) 1.303 <0.001 41 (26-52) 42 (32-50) 0.119 0.33
Women 60 (41) 276 (21) 0.431 <0.001 56 (40) 53 (38) 0.044 0.71
Height, cm 176 (168-186) 176 (170-182) 0.072 0.52 176 (168-185) 178 (170-185) 0.129 0.30
Weight, kg 78 (65-90) 80 (72-90) 0.235 0.01 78 (65-90) 79 (68-90) 0.174 0.31
Diagnosis 0.715 <0.001 0.061 0.66
Ischemic cardiomyopathy 27 (18) 841 (64) 26 (19) 41 (29)
Genetic arrhythmia syndrome 79 (53) 240 (18) 75 (54) 54 (39)
Nonischemic cardiomyopathy 30 (20) 179 (14) 28 (20) 30 (21)
Congenital heart disease 5 (3) 49 (4) 5 (4) 12 (9)
Family history of SCD 7 (5) 3 (0) 6 (4) 3 (2)
QRS duration in ms 98 (90-108) 104 (90-120) 0.373 <0.001 98 (88-108) 100 (90-113) 0.135 0.22
Hypertension 30 (20) 503 (42) 0.488 <0.001 30 (21) 34 (24) 0.069 0.56
Primary prevention 97 (66) 820 (63) 0.063 0.53 93 (66) 86 (61) 0.105 0.38
Left ventricular ejection fraction, % 50 34 0.381 <0.001 50 49 0.031 0.91
De novo implant 128 (87) 1,261 (96) 0.346 <0.001 121 (86) 125 (89) 0.083 0.47
Coronary artery bypass graft 3 (2) 317 (24) 0.649 <0.001 3 (2) 3 (2) 0.000 1
Myocardial infarction 34 (23) 695 (53) 0.649 <0.001 33 (24) 38 (27) 0.084 0.48
Diabetes 8 (5) 233 (19) 0.413 <0.001 8 (6) 5 (4) 0.092 0.62
Atrial ﬁbrillation 14 (10) 320 (24) 0.407 <0.001 13 (9) 21 (15) 0.0196 0.14
Renal function 0.280 0.002 0.000 1
Good (eGFR >60 ml/min) 134 (91) 1,024 (81) 128 (91) 129 (92)
Moderate (eGFR 30–60 ml/min) 11 (8) 214 (17) 10 (7) 8 (6)
Poor (eGFR <30 ml/min) 2 (1) 31 (2) 2 (1) 3 (2)
NYHA functional class 0.529 0.005 0.013 0.92
I 109 (74) 643 (49) 103 (74) 102 (73)
II 31 (21) 489 (38) 30 (21) 31 (22)
III 7 (5) 162 (12) 7 (5) 7 (5)
IV 0 (0) 11 (1) 0 (0) 0 (0)
Values are median (interquartile range), n (%), or %. *Standardized mean difference is the difference in group means divided by the control standard deviation. Absolute values<0.2 suggest balance between
propensity-matched groups.
eGFR ¼ estimated glomerular ﬁltration rate; NYHA ¼ New York Heart Association; S-ICD ¼ subcutaneous implantable cardioverter-deﬁbrillator; SCD ¼ sudden cardiac death; TV-ICD ¼ transvenous
implantable cardioverter-deﬁbrillator.
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2049ANALYSIS OF THE MATCHED COHORT. Baseline
variables of the matched cohort were compared with
paired tests, McNemar and Wilcoxon signed rank, and
standardized mean differences were calculated. We
used the Kaplan-Meier method to correct for differ-
ences in follow-up and estimate the cumulative
incidence of outcomes at 5-year follow-up. p Values
and hazard ratios (HRs) were calculated using condi-
tional proportional hazards models with adjustment
for ICD programming. Conditional proportional haz-
ards assumptions were visually inspected by plotting
Schoenfeld residuals.
SENSITIVITY ANALYSES. A sensitivity analysis was
performed excluding patients exposed to transient
external factors: patients implanted with advisory
leads, that is, Medtronic Sprint Fidelis and St. Jude
Medical Riata (n ¼ 20) in the TV-ICD group, and an
equal number of patients exposed to the operators’learning curve in the S-ICD group (15,16). Addition-
ally, a sensitivity analysis for patients with a left
ventricular ejection fraction #35% was performed.
All statistical analyses were conducted in R Studio
and R version 3.2.2 and the package MatchIt for pro-
pensity matching (17,18). All reported p values were
2-tailed, and p < 0.05 was considered statistically
signiﬁcant.
RESULTS
ENTIRE COHORT. In the entire cohort, before
matching, most baseline variables were signiﬁcantly
different between the 2 groups (Table 1, left columns).
The characteristics of the TV-ICD group represent a
typical ICD cohort, with ischemic cardiomyopathy as
the predominant diagnosis (64%), signiﬁcant cardio-
vascular comorbidity, and a median left ventricular
ejection fraction of 34%. The S-ICD group is younger,
CENTRAL ILLUSTRATION Outcomes Comparison of S-ICD and TV-ICD Therapy: Device-Related Complications
Brouwer, T.F. et al. J Am Coll Cardiol. 2016;68(19):2047–55.
Kaplan-Meier plot of device-related complications in the subcutaneous and transvenous ICD patients in the propensity-matched cohort. ICD ¼ implantable cardioverter-
deﬁbrillator; S-ICD ¼ subcutaneous implantable cardioverter-deﬁbrillator; TV-ICD ¼ transvenous implantable cardioverter-deﬁbrillator.
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2050with less comorbidity, higher left ventricular ejection
fractions (50%), and genetic arrhythmia syndromes as
the main diagnosis (53%).
PROPENSITY-MATCHED COHORT. In the propensity-
matched cohort, S-ICD cases (n ¼ 140) were similar to
their TV-ICD controls (n ¼ 140), with no signiﬁcant
differences in any baseline characteristics (Table 1,
right columns). Compared with the entire cohort, the
matched cohort was younger, with a median age of 41
years (IQR: 30 to 52 years) and had a higher left
ventricular ejection fraction. In the TV-ICD group, 124
devices (88.6%) were dual-chamber and 16 (11.4%)
were single-chamber. The median follow-up duration
was longer in the TV-ICD group than in the S-ICD
group: 5 years versus 3 years, respectively (p < 0.001).
ICD PROGRAMMING. The conditional zones in S-ICDs
and the fast VT zones in TV-ICDs were similar, with amedian of 190 beats/min (IQR: 180 to 200 beats/min)
and 188 beats/min (IQR: 188 to 200 beats/min),
respectively; p ¼ 0.77. The unconditional zone in the
S-ICD and VF zone in the TV-ICD differed, with me-
dians of 250 beats/min (IQR: 250 to 250 beats/min) and
231 beats/min (IQR: 230 to 231 beats/min), respec-
tively; p < 0.001. Deﬁbrillation testing was performed
in 92% of S-ICD and 97% of TV-ICD patients. There
were 13 patients (9.3%) in the TV-ICD group with >5%
bradycardia pacing (atrial or ventricular) in the ﬁrst
year. In the S-ICD group, 6 patients (4.3%) had a
concomitant transvenous pacemaker.
CLINICAL OUTCOMES. Compl i cat ions . The compli-
cation rate at 5 years of follow-up was 13.7%
(95% CI: 6.4% to 20.3%) in the S-ICD group versus
18.0% (95% CI: 10.5% to 24.8%) in the TV-ICD group;
p ¼ 0.80 (Central Illustration). Table 2 presents the
TABLE 2 Clinical Endpoints*
Complications S-ICD
KM
Rate, % TV-ICD
KM
Rate, %
Total 14 13.7 21 18.0
Lead (total) 1 17
Atrial lead failure 3 2.9
Deﬁbrillation lead failure 0 0 10 8.5
Atrial and deﬁbrillation
lead failure
3 2.9
Displacement 1 0.8 1 0.7
Infection 5 4.1 4 3.6
Erosion 3 3.0 2 1.5
DFT failure 1 0.7 0 0
Inappropriate sensing 2 3.2 0 0
Twiddler syndrome 1 1.1 1 0.8
Device failure 1 1.1 0 0
Pneumothorax 0 0 0 0
Appropriate therapy 12 17.0 39 31.3
ATP 28 21.8
Shock 12 17.0 24 21.3
Inappropriate shocks 20 22
Oversensing 17 17.1 1 1.2
Supraventricular tachycardia 3 4.2 21 17.6
Deceased 2 6
Noncardiac 1 2.0 3 2.6
Cardiac 1 2.0 2 1.7
Unknown 0 0 1 0.9
*Crude number of patients in the ﬁrst 5 years and the adjusted Kaplan-Meier rate
for the follow-up duration.
ATP ¼ antitachycardia pacing; DFT ¼ deﬁbrillation threshold testing;
KM ¼ Kaplan-Meier; other abbreviations as in Table 1.
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cations, and the Kaplan-Meier complication rate,
corrected for follow-up duration. Lead compli-
cations necessitating surgical intervention that was
not performed during elective pulse generator
replacement occurred more often in the TV-ICD
group (11.5%; 95% CI: 5.3% to 17.2%) compared with
the S-ICD group (0.8%; 95% CI: 0.0% to 2.2%),
p ¼ 0.03 (Figure 1A). Infections occurred in 4.1%
(95% CI: 0.5% to 7.7%) of the S-ICD group and in 3.6%
(95% CI: 0.0% to 7.1%) of the TV-ICD group; p ¼ 0.36
(Figure 1B). There were 2 patients with bacteremia in
the TV-ICD group and 1 in the S-ICD group, who also
had a concomitant transvenous pacemaker. S-ICD
patients had more nonlead-related complications
(pocket erosion, deﬁbrillation threshold testing
failure, and device failure) than TV-ICD patients:
9.9% (95% CI: 2.0% to 15.4%) and 2.2% (95% CI: 0.0%
to 4.6%), respectively; p ¼ 0.047 (Figure 1C). Lead
survival was signiﬁcantly longer in the S-ICD group:
99.2% (95% CI: 97.8% to 100.0%) compared with
the TV-ICD group 85.9% (95% CI: 78.46% to 92.7%);
p ¼ 0.02 (Figure 1D).APPROPRIATE ICD INTERVENTIONS. Appropriate
ICD intervention rates (shocks and ATP) were lower in
the S-ICD group, at 17.0% (95% CI: 6.3% to 26.4%)
versus 31.3% (95% CI: 22.6% to 39.7%) (Figure 2A). In
the Cox proportional hazards model adjusted for ICD
programming, the HR for appropriate intervention for
the TV-ICD group was 2.42; p ¼ 0.01. Appropriate
shock rates were 17% (95% CI: 6.3% to 26.4%) in the
S-ICD group and 21.3% (95% CI: 12.6% to 27.3%) in the
TV-ICD group (Figure 2B). In the Cox proportional
hazards model with adjustment for ICD programming,
this difference was not signiﬁcant: TV-ICD HR: 1.46,
p ¼ 0.36.
INAPPROPRIATE ICD INTERVENTIONS. Inappro-
priate ICD interventions (shocks and ATP) were 20.5%
(95% CI: 11.5% to 28.6%) in the S-ICD group versus
29.7% (95% CI: 19.7% to 37.6%) in the TV-ICD group
(Figure 2C). The HR for inappropriate therapy,
adjusted for ICD programming, in the TV-ICD group
was 1.29; p ¼ 0.42. The percentage of patients who
experienced inappropriate shocks was 20.5% (95% CI:
11.5% to 28.6%) in the S-ICD group and 19.1% (95% CI:
11.6% to 26.0%) in the TV-ICD group (Figure 2D). This
difference was not signiﬁcantly different after
adjustment for programming (HR: 0.85 for TV-ICD
group; p ¼ 0.64). In 94%, inappropriate shocks from
TV-ICDs were for supraventricular tachycardia (atrial
ﬁbrillation, atrial ﬂutter, and sinus tachycardia).
Inappropriate shocks in S-ICD patients were for
oversensing in 85% and for supraventricular tachy-
cardia in 15%.
FOLLOW-UP. Five-year patient survival was 96.0%
(95% CI: 90.1% to 100.0%) in the S-ICD arm and 94.8%
(95% CI: 90.7% to 99.0%) in the TV-ICD arm; p ¼ 0.42.
Pulse generator replacement due to battery depletion
did not differ at the 5-year follow-up; p ¼ 0.18. Of
S-ICD patients, 1.3% (95% CI: 0.0% to 3.7%) were
upgraded to a TV-ICD or cardiac synchronization
therapy device versus 4.6% (95% CI: 0.5% to 8.5%) in
the TV-ICD group; p ¼ 0.26.
SENSITIVITY ANALYSES. The ﬁrst sensitivity anal-
ysis, which excluded 20 patients implanted with
advisory leads (Medtronic Sprint Fidelis and St. Jude
Medical Riata) and the 20 chronologically ﬁrst S-ICD
implants (to account for the learning curve), did not
show a difference in clinical outcomes compared with
the primary analysis (Online Table 2 and Online
Figures 2 to 11). The complication rate at the 5-year
follow-up was 14.0% (95% CI: 5.4% to 21.8%) in the
S-ICD group versus 13.8% (95% CI: 6.3% to 20.7%) in
the TV-ICD group; p ¼ 0.36. Of the 20 TV-ICD patients
implanted with advisory leads, 8 (41%, 95% CI:
14.6% to 59.7%) leads failed at 5 years. In the
FIGURE 1 Device-Related Complications per Type
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2052chronologically ﬁrst 20 S-ICD implants, there were 3
(15%, 95% CI: 0.0% to 29.3%) complications at the
5-year follow-up.
The second sensitivity analysis, which included
patients with left ventricular ejection fractions #35%,
yielded 38 S-ICD and 51 TV-ICD patients with median
ejection fractions of 25% and 28%, respectively. None
of the comparisons for clinical outcomes demon-
strated a signiﬁcant difference between the S-ICD and
the TV-ICD patients, and trends were similar except
for a nonsigniﬁcant trend towards more inappropriate
shocks in the S-ICD arm (Online Table 3, Online
Figures 12 to 21).
DISCUSSION
MAIN FINDINGS. The current study provides the ﬁrst
balanced comparison of S-ICD and TV-ICD therapy
for clinical outcomes during long-term follow-up.The main ﬁndings of this study are as follows: the
complication rate was similar, but the nature of the
complications differed signiﬁcantly. Appropriate and
inappropriate shocks were delivered at equal rates in
both groups. TV-ICD patients received more appro-
priate and inappropriate therapy when ATP was also
taken into account.
COMPLICATIONS. The complication rates in both
groups were similar, but the nature of complications
differed signiﬁcantly, as could be expected due to the
different designs of the devices. The weakest link of
the TV-ICD system is the lead, which remained true
after exclusion of advisory leads. In the S-ICD group,
inappropriate sensing resulted in explantation of the
device in 1 patient and in the need for lead reposi-
tioning in another. Improvements of the S-ICD algo-
rithm may avoid sensing issues. The observed
complication rate at the 5-year follow-up is similar to
that in the SCD-HeFT (Sudden Cardiac Death in Heart
FIGURE 2 Appropriate and Inappropriate ICD Therapy
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Kaplan-Meier plot of: (A) appropriate therapy (ATP and shocks); (B) appropriate shocks; (C) inappropriate therapy (ATP and shocks);
and (D) inappropriate shocks. Hazard ratios are adjusted for implantable cardioverter-deﬁbrillator programming. ATP ¼ antitachycardia pacing;
other abbreviations as in Figure 1.
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2053Failure Trial) (9% acute and 5% long-term complica-
tions during 3.8 years of follow-up) and previous re-
ports on complications in younger patients (22%
during 4.5 years of follow-up) (2,19).
THERAPY. The difference in appropriate therapy may
be explained by the ability of TV-ICDs to deliver ATP
instantly after VT detection, whereas the S-ICD has a
longer charging time, which allows nonsustained VTs
to terminate. Although ATP has been demonstrated to
successfully terminate approximately 70% of VT
episodes, it did not result in fewer appropriate shocks
in this cohort (20–23). This may be explained by the
fact that patients with ischemic scars represented a
minority in this study.
The incidences of inappropriate therapy and
inappropriate shocks were high in both groups, but
are in line with a previous publication on younger
ICD patients (19). The reasons for inappropriateshocks differed between the 2 groups: the majority
of inappropriate shocks by TV-ICDs were for supra-
ventricular tachycardia and those by S-ICDs were for
cardiac over-sensing.
OTHER ENDPOINTS. This study did not ﬁnd a dif-
ference in patient survival rate, but may be under-
powered to detect such a difference. None of the
patients died of SCD and all spontaneous ventricular
arrhythmias were successfully treated in both groups.
The number of patients that required upgrade to a
CRT device was low, but similar to what has previ-
ously been reported (24). The shorter battery
longevity of the S-ICD, as projected by the manufac-
turer, was not detected in this analysis, but is likely to
be demonstrated with longer follow-up.
SENSITIVITY ANALYSES. The ﬁrst analysis excluded
patients that were implanted with advisory leads
in the TV-ICD group and during the S-ICD
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: S-ICD devices reduce
lead-related complications compared with TV-ICDs,
but not the overall complication rate, which includes
delivery of inappropriate shocks.
TRANSLATIONAL OUTLOOK: Randomized trials
that encompass larger, more diverse patient cohorts
and longer follow-up are needed to clarify the ad-
vantages and disadvantages of these 2 approaches to
ICD therapy.
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2054implanter’s learning curve. The second analysis only
included patients with a left ventricular ejection
fraction #35%. Both sensitivity analyses yielded re-
sults similar to the primary analysis with the com-
plete matched cohort.
CLINICAL IMPLICATIONS. This study demonstrates
that the S-ICD has a signiﬁcant beneﬁt over TV-ICDs
with respect to lead-related complications. This
beneﬁt may be greater with longer follow-up. The
rate of nonlead-related complications in the S-ICD
group may decrease when the technology is fully
matured.
Therefore, in the choice of device type, the risk of
lead-related complications versus nonlead-related
complications needs to be taken into account, as
well as the speciﬁc limitations of the S-ICD, including
the lack of pacing capabilities and the larger pulse
generator size. The consideration of device type also
needs to include recommended deﬁbrillation testing
in S-ICD implants, which may be omitted in TV-ICDs
(25,26). It is likely that the shorter battery longevity
of the S-ICD will require more frequent replacements,
which are associated with speciﬁc risks (27).
STUDY LIMITATIONS. First, patients included in the
primary analysis represent a category of young ICD
patients with little comorbidity from 2 centers, which
may limit generalizability to the broader ICD popu-
lation, Furthermore, only approximately 15% of all
TV-ICD patients from LUMC were included in the
analysis. Second, although there were no differences
in baseline characteristics in the matched cohort, we
cannot exclude residual confounding of unmeasured
variables, such as pacing indication at time of
implant, due to the nonrandomized character of the
study. Third, the match between S-ICD and TV-ICD
patients would have been more optimal with a
higher rate of single-chamber ICDs, because single-
chamber ICDs are associated with an approximately
1% lower rate of major complications compared with
dual-chamber ICDs during short-term follow-up(3,28). The observed rate of dual-chamber ICDs
resulted from the implanter’s preference, as opposed
to a need for chronic bradycardia pacing, a tendency
that was also reported in another large cohort (28).
Fourth, there may be hospital bias present. This was
explored by comparing dual-chamber ICD complica-
tions in both centers, which did not reveal a
difference.
CONCLUSIONS
In this matched cohort of S-ICD and mostly dual-
chamber TV-ICD patients, complication rates were
similar, although their nature differed. The S-ICD
effectively reduced lead-related complications at the
cost of nonlead-related complications. Both appro-
priate and inappropriate shock rates were similar.
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